Tag: biotech
-
Perimeter Medical Imaging (PINK.V) successfully commercializes their breast cancer technology
In the biotech/medtech world, the steps to viability as a company are proving your technology works, getting that technology approved by the FDA, finding doctors who are interested in using it, and commercializing the product so it can be manufactured to scale. Perimeter Medical Imaging (PINK.V) just made it through the final boss level. Perimeter…
-
![Mountain Valley MD Holdings (MVMD.C) new patent and preclinicals put cancer in their sights]()
Mountain Valley MD Holdings (MVMD.C) new patent and preclinicals put cancer in their sights
Mountain Valley MD Holdings (MVMD.C) filed a cancer patent and is moving forward with preclinical trials with third party cancer research organizations (CROs) in triple-negative breast cancer, metastatic melanoma and lung carcinoma, according to a press release. The patent is called Novel Injectable, Infusable, Instillable Ivermectin Adjuvant for Cancer Therapies, and involves solubilized ivermectin (also…
-
![Revive Therapeutics (RVV.C) latest spate of Bucillamine research could slow COVID-19 infection rates]()
Revive Therapeutics (RVV.C) latest spate of Bucillamine research could slow COVID-19 infection rates
Revive Therapeutics (RVV.C) signed a research agreement with the University of California, San Francisco (UCSF) to explore Bucillamine as a potential treatment for severe cases of COVID-19 today, according to a press release. The research will be done by Dr. John Fahy with the intention of testing the efficacy of Bucillamine in pre-clinical models of…
-
![Predictmedix (PMED.C) engages global investment bank to prep for NASDAQ listing]()
Predictmedix (PMED.C) engages global investment bank to prep for NASDAQ listing
The Nasdaq Exchange has 3,300 listed stocks including giants such as Apple (AAPL.Q), Google (GOOG.Q), Microsoft (MSFT.Q), Oracle (ORCL.Q), Amazon (AMZN.Q), and Intel (INTC.Q).
-
Parry Special: Short report on Mountain Valley MD Holdings (MVMD.C) earns nothing but rage
When a ‘devastating’ expose on a company opens with the line ‘We are short this company’, I have to say, I find it hard to read much further. To open the discussion admitting you’ll make more money if the company you’re writing about gets obliterated, and then proceed to map out your obliteration strategy, well…
-
![Diagnos (ADK.V) uses AI and telemedicine to scan your eye for health issues in 16 countries]()
Diagnos (ADK.V) uses AI and telemedicine to scan your eye for health issues in 16 countries
In a world where companies toss the term ‘artificial intelligence’ around whenever the office intern figures out how to get a spreadsheet pie chart to update automatically, it’s nice to see a company utilizing actual AI and machine learning in a manner that involves actual intelligence and learning. Diagnos (ADK.V) is a health tech deal…
-
![As Australia opens to cannabis, Canntab’s (PILL.C) tech might just claim the box seat]()
As Australia opens to cannabis, Canntab’s (PILL.C) tech might just claim the box seat
News this week that Canntab Therapeutics (PILL.C) received an Australian patent for their hard-pressed cannabis pill tech, to match those received earlier in North America, didn’t launch the stock into space. That’s understandable, to be honest, as North American investors have taken an eye off the island continent and its slow roll to weed legalization…
-
![Canntab Therapeutics (PILL.C) racks up revenue as CBD caplets shipped to Medipharm (LABS.T)]()
Canntab Therapeutics (PILL.C) racks up revenue as CBD caplets shipped to Medipharm (LABS.T)
Cannabis hard tablet IP holder Canntab Therapeutics (PILL.C) continues to send product to market, announcing Wednesday they’ve fulfilled 80% of their contract with Medipharm Labs (LABS.T), bringing in another half million dollars in revenue toward the $1.3 million deal announced last June. Orders under the agreement are a mix of Canntab’s proprietary instant release tablets…
-
![Revive Therapeutics (RVV.C) finds $23 million and throws it at their bucillamine clinical studies]()
Revive Therapeutics (RVV.C) finds $23 million and throws it at their bucillamine clinical studies
Revive Therapeutics (RVV.C) provided an update on their Phase 3 clinical trial for bucillamine for COVID-19 today. Primarily, the update’s about funding and more specifically their recent $23 million financing. The company intends to use the monies to fund their aggressive expansion from14 clinical sites to 50 to meet their enrolment requires for the study…
-
![Perimeter Medical Imaging AI (PINK.V) technology advances as ACS reports 2.3 million new breast cancer cases]()
Perimeter Medical Imaging AI (PINK.V) technology advances as ACS reports 2.3 million new breast cancer cases
In 25% of Breast Lumpectomy surgeries, cancerous material is left behind. With current technology, the surgeon needs to wait about a week, to see if he’s got all the cancerous material.
